Home
HelpTest Code CA2729 Breast Cancer Antigen (CA 27.29)
Useful For
The test is intended for use as aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing or CA27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.
Synonyms/Keywords
Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 , (CA 27.29), MAM 6, Milk Mucin, CA 27-29
Specimen Requirements
| Specimen Type | Preferred Container/Tube | Acceptable Container/Tube | Specimen Volume | Specimen Minimum Volume (allows for 1 repeat) |
Pediatric Minimum Volume (no repeat) |
|---|---|---|---|---|---|
| Serum | Serum Separator Tube (SST) | Red Top Tube (RTT) | 0.5 mL | 0.3 mL | 0.25 mL |
Collection/Processing Instructions
Serum gel tubes should be centrifuged within 2 hours of collection.
Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.
Tightly cap and refrigerate specimens at 2-8° Celsius for storage and transport.
Freeze samples at or below -20° Celsius if the sample is not assayed within 7 days.
Freeze samples only once and mix thoroughly after thawing.
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Frozen (preferred) | 90 days |
| Refrigerated | 7 days | |
| Room Temperature | 4 days |
Rejection Criteria
| Samples not meeting storage conditions | |
|---|---|
| Grossly icteric samples |
Interferences
Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this inteference and anomalous values may be observed. Additional information may be required.
There are no known cross-reactants for CA 27.29.
Interpretations
Increased levels of CA 27.29 (>38 U/mL) may indicate recurrent disease in a woman with treated breast carcinoma.
Assay is not intended for use as a screening test or for diagnosis.
Normal levels of CA 27.29 as absolute evidence to the presence of the absence of malignant disease.
Before treatment, patients with confirmed breast carcinoma frequently have levels of CA 27.29 within the range observed in healthy individuals. Additionally, elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases.
Measurements of CA 27.29 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
Exercise caution when interpreting CA 27.29 levels during pregnancy.
The concentration of CA 27.29 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity. CA 27.29 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.
Reference Range Information
≤38.6 U/mL
Marshfield Labs Performing Department
Marshfield Labs Chemistry
Performing Information
| Performing Location | Day(s) Test Performed | Analytical Time | Methodology/Instrumentation |
|---|---|---|---|
| Marshfield | Monday, Wednesday, and Friday | 60 minutes | Competitive Immunoassay using Direct Chemiluminometric Technology/Siemens Centaur XP |
CPT Codes
| CPT | Modifier (if needed) |
Quantity | Description | Comments |
|---|---|---|---|---|
| 86300 |
Outreach CPT Codes
| CPT | Modifier (if needed) |
Quantity | Description | Comments |
|---|---|---|---|---|
| 86300 |
Ordering Applications
| Ordering Application | Description |
|---|---|
| Cerner | Breast Ca Antigen (CA 27.29) |